Assessing the Influence of ICER Reports on U.S. Payer Decision Making

The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute for Health and Care Excellence (NICE) assessments in the U.K., public reports on a product’s value are bound to influence discussions and negotiations between payers and manufacturers. However, the extent to which payers consider ICER assessments in their evaluation of therapies remains unclear.

To address this uncertainty, Trinity Life Sciences conducted a payer survey to better understand how U.S. payers really use ICER assessments. The goal was to shine a light on the impact ICER assessments and other third-party economic assessments truly have on the formulary decision making process and perceptions of price. In this advisory brief, we share key findings that emerged from our research to provide guidance for life sciences manufacturers.

Complete the form below to access the full advisory brief

We would contact you in accordance with our Privacy Policy, which we invite you to visit for details about our data privacy practices, including, where appropriate, how you may access and correct the personal data we store or withdraw consent to the collection, use or disclosure of such information. We will not share your email address or personal information. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.